Pavlos Msaouel, MD, PhD
Advertisement
Articles by Pavlos Msaouel, MD, PhD
Pavlos Msaouel, MD, PhD, discusses how the treatments and outcomes differ between patients with the rarer disease of renal medullary carcinoma than the more common renal cell carcinoma.
Advertisement
Latest Updated Articles
Treatments Differ in Rare Versus More Common Kidney CancersPublished: November 6th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
2
T-DXd Plus Pertuzumab Yields Favorable Benefit Over SOC in HER2+ Breast Cancer
3
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
4
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
5
